Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1201 in advanced cancer
NCT04257617Phase 1Completed
- Sponsor
- Zai Lab
- Start
- May 2020
- Primary completion
- May 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ZL-1201 in solid tumor (advanced stage) and lymphoma, sponsored by Zai Lab. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started May 2020; status: completed.
02
Drugs
ZL-1201
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT04257617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04257617.